Skip to Main Content

INFORMATION FOR

Michael Schilsky, MD

Professor of Medicine; Medical Director, Adult Liver Transplant at Yale-New Haven Transplantation Center

Contact Information

Michael Schilsky, MD

Mailing Address

  • Yale School of Medicine

    Department of Medicine (Digestive Diseases), PO Box 208019

    New Haven, CT 06520-8019

    United States

Research Summary

I participate as an investigator in the NIH sponsored Acute Liver Failure Study Group. I am an investigator in clinical trials for patients with Wilson disease and advanced liver disease.

Extensive Research Description

I participate as an investigator in the NIH sponsored Acute Liver Failure Study Group where we have been focusing on patients with acute liver failure to advance our understanding of this uncommon disorder.

I am an investigator in clinical trials for patients with Wilson disease, including the testing of once daily use of trientine for maintenance therapy, and the novel agent WTX 101 (choline-tetrathiomolybdate).


Coauthors

Research Interests

Copper; Liver Transplantation; Liver Failure, Acute

Selected Publications

  • O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trialWeiss K, Weiss K, Schilsky M, Czlonkowska A, Czlonkowska A, Askari F, Askari F, Ala A, Ala A, Ferenci P, Ferenci P, Ott P, Ott P, Abdurakhmanov D, Abdurakhmanov D, Szalay F, Szalay F, Socha P, Socha P, Shimizu N, Shimizu N, Bronstein J, Bronstein J, Bega D, Bega D, Hahn S, Hahn S, Swenson E, Chen Y, Chen Y, Poujois A, Poujois A. O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial 2022, a1-a1. DOI: 10.1136/gutjnl-2022-basl.1.
  • FRI297 Defining the boundaries for “stability” in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trialKamlin C, Schilsky M, Ott P, Weiss K, Zuin M, Poujois A, Ala A, D’Hollander K. FRI297 Defining the boundaries for “stability” in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trial Journal Of Hepatology 2022, 77: s539. DOI: 10.1016/s0168-8278(22)01402-7.
  • GS001 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trialWeiss K, Weiss K, Schilsky M, Czlonkowska A, Czlonkowska A, Askari F, Askari F, Ala A, Ala A, Ferenci P, Ferenci P, Ott P, Ott P, Abdurakhmanov D, Abdurakhmanov D, Szalay F, Szalay F, Socha P, Socha P, Shimizu N, Shimizu N, Bronstein J, Bronstein J, Bega D, Bega D, Hahn S, Hahn S, Swenson E, Chen Y, Chen Y, Poujois A, Poujois A. GS001 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial Journal Of Hepatology 2022, 77: s1. DOI: 10.1016/s0168-8278(22)00428-7.
  • OS077 Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trialSchilsky M, Poujois A, Zuin M, Ott P, Weiss K, Cassiman D, Ala A, Czlonkowska A, Dubois N, Amin N, Kamlin C. OS077 Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trial Journal Of Hepatology 2022, 77: s61-s62. DOI: 10.1016/s0168-8278(22)00524-4.
  • Résultats à un an de l’étude chelate : comparaison de la trientine tétrahydrochloride à la D-Pénicillamine chez des patients stables atteints de la maladie de WilsonPoujois A, Giovanni Z, Anna C, Obadia M, Henry A, Weiss K, Schilsky M. Résultats à un an de l’étude chelate : comparaison de la trientine tétrahydrochloride à la D-Pénicillamine chez des patients stables atteints de la maladie de Wilson Revue Neurologique 2022, 178: s47. DOI: 10.1016/j.neurol.2022.02.226.
  • Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisationZuin M, Czlonkowska A, Cassiman D, Poujois A, Ott P, Dubois N, Weiss K, Monico S, Battezzati P, Carnevali G, Schilsky M, Investigators C. Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisation Digestive And Liver Disease 2022, 54: s2. DOI: 10.1016/j.dld.2022.01.007.
  • Recent advances in Wilson diseaseMoini M, To U, Schilsky M. Recent advances in Wilson disease Translational Gastroenterology And Hepatology 2021, 6: 21-21. DOI: 10.21037/tgh-2019-rld-10.
  • P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson diseaseCamarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Coskun A, Patel A, Wadhwa A, Apdik T, Tomlin R, Deng Y, Gonzalez-Peralta R, Schilsky M. P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson disease Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.23.
  • P13 Major depressive disorder in patients with wilson’s disease: relationship with liver disease, neurological disease and quality of lifeCamarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Patel A, Wadhwa A, Coskun A, Apdik T, Tomlin R, Deng Y, Schilsky M. P13 Major depressive disorder in patients with wilson’s disease: relationship with liver disease, neurological disease and quality of life Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.24.
  • FRI303 Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of lifeCamarata M, Ala A, To U, Zimbrean P, Rubman S, Patel A, Wadhwa A, Maciejewski K, Song X, Deng Y, Tomlin R, Apdik T, Coskun A, Schilsky M. FRI303 Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of life Journal Of Hepatology 2020, 73: s550-s551. DOI: 10.1016/s0168-8278(20)31573-7.
  • 257 Bipolar disorder in patients with Wilson diseaseZimbrean P, Rubman S, Maciejewski K, Coskun, Nalamada K, Camarata M, Tomlin R, Patel A, To U, Ala A, Gonzalez-Peralta R, Deng Y, Schilsky M. 257 Bipolar disorder in patients with Wilson disease Journal Of Psychosomatic Research 2020, 133: 110055. DOI: 10.1016/j.jpsychores.2020.110055.
  • Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ diseaseSchilsky M, Mistry P. Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ disease 2020, c12.7.2-c12.7.2.s26. DOI: 10.1093/med/9780198746690.003.0234.
  • Major depressive disorder in patients with Wilson diseaseZimbrean P, Gold S, Nalamada K, Camarata M, Tomlin R, Patel A, Vives-Rodrigues A, Ekong U, Bramford N, Valentino P, To U, Deng Y, Song X, Ala A, Schilsky M. Major depressive disorder in patients with Wilson disease Journal Of Psychosomatic Research 2019, 121: 148. DOI: 10.1016/j.jpsychores.2019.03.145.
  • FRI-425-Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc saltsCamarata M, Ala A, Schilsky M. FRI-425-Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc salts Journal Of Hepatology 2019, 70: e581. DOI: 10.1016/s0618-8278(19)31162-4.
  • Wilson's DiseaseKelly C, Ala A, Schilsky M. Wilson's Disease 2019, 554-573. DOI: 10.1002/9781119211419.ch37.
  • Chapter 39 New Treatment Modalities in Wilson DiseaseSchilsky M. Chapter 39 New Treatment Modalities in Wilson Disease 2019, 399-405. DOI: 10.1016/b978-0-12-810532-0.00039-2.
  • Chapter 15 General Considerations and the Need for Liver TransplantationCamarata M, Weiss K, Schilsky M. Chapter 15 General Considerations and the Need for Liver Transplantation 2019, 173-182. DOI: 10.1016/b978-0-12-811077-5.00015-3.
  • Chapter 23 Special Treatment Considerations for Wilson DiseaseCamarata M, Weiss K, Schilsky M. Chapter 23 Special Treatment Considerations for Wilson Disease 2019, 235-245. DOI: 10.1016/b978-0-12-811077-5.00023-2.
  • The Epidemiology of Rare Hereditary Metabolic Liver DiseasesPericleous M, Kelly C, Ala A, Schilsky M. The Epidemiology of Rare Hereditary Metabolic Liver Diseases 2018, 307-330. DOI: 10.1007/978-3-319-94355-8_17.
  • Introduction to Copper Metabolism and Wilson DiseaseTo U, Schilsky M. Introduction to Copper Metabolism and Wilson Disease 2018, 1-16. DOI: 10.1007/978-3-319-91527-2_1.
  • Monitoring Treatment of Wilson DiseaseMiloh T, Schilsky M. Monitoring Treatment of Wilson Disease 2018, 143-159. DOI: 10.1007/978-3-319-91527-2_8.
  • Wilson Disease: Special CircumstancesCamarata M, Schilsky M. Wilson Disease: Special Circumstances 2018, 175-181. DOI: 10.1007/978-3-319-91527-2_10.
  • Liver Transplantation for Wilson DiseaseMiloh T, Schilsky M. Liver Transplantation for Wilson Disease 2018, 183-202. DOI: 10.1007/978-3-319-91527-2_11.
  • Treatment Options for Wilson DiseaseKelly C, Pericleous M, Schilsky M. Treatment Options for Wilson Disease 2018, 45-61. DOI: 10.1007/978-3-319-91527-2_3.
  • Treating Other Symptoms of Wilson Disease: The LiverCamarata M, Schilsky M. Treating Other Symptoms of Wilson Disease: The Liver 2018, 87-106. DOI: 10.1007/978-3-319-91527-2_5.
  • Diagnosis Confirmation and Screening of Wilson DiseasePericleous M, Kelly C, Schilsky M. Diagnosis Confirmation and Screening of Wilson Disease 2018, 17-44. DOI: 10.1007/978-3-319-91527-2_2.
  • Partnering for Care of Wilson DiseaseGraper M, Schilsky M. Partnering for Care of Wilson Disease 2018, 203-212. DOI: 10.1007/978-3-319-91527-2_12.
  • Posters Thursday, 12 April 2018Weiss K, Askari F, Ferenci P, Ala A, Czlonkowska A, Nicholl D, Bronstein J, Bega D, Schilsky M. Posters Thursday, 12 April 2018 Journal Of Hepatology 2018, 68: s105-s364. DOI: 10.1016/s0168-8278(18)30428-8.
  • Chapter 19 Wilson Disease and Related DisordersSchilsky M. Chapter 19 Wilson Disease and Related Disorders 2018, 253-268. DOI: 10.1016/b978-0-323-47874-8.00019-5.
  • Update on Wilson disease: focus on WTX-101Camarata M, Ala A, Schilsky M. Update on Wilson disease: focus on WTX-101 Drugs Of The Future 2018, 43: 501. DOI: 10.1358/dof.2018.043.07.2819432.
  • Wilson DiseaseSchilsky M, Ala A. Wilson Disease 2017, 799-819. DOI: 10.1002/9781119251316.ch29.
  • GS-016 WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trialWeiss K, Askari F, Ferenci P, Ala A, Czlonkowska A, Nicholl D, Bronstein J, Bega D, Schilsky M. GS-016 WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trial Journal Of Hepatology 2017, 66: s88. DOI: 10.1016/s0168-8278(17)30440-3.
  • PS020 An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early ObservationsWeiss K, Ala A, Askari F, Bega D, Bronstein J, Czlonkowska A, Ferenci P, Nicholl D, Schilsky M. PS020 An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations Journal Of Hepatology 2016, 64: s145-s146. DOI: 10.1016/s0168-8278(16)00033-7.
  • Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational CohortDo A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.
  • P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patientsWeiss K, Askari F, Ferenci P, Czlonkowska A, Bronstein J, Schilsky M, Clark D, Hansson J. P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patients Journal Of Hepatology 2015, 62: s847. DOI: 10.1016/s0168-8278(15)31492-6.
  • Su1011 Should Liver Transplantation Be Reconsidered in Patients With Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Regression Analysis of Epidemiologic EvidenceNjei B, Schilsky M, Ditah I, Taddei T. Su1011 Should Liver Transplantation Be Reconsidered in Patients With Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Regression Analysis of Epidemiologic Evidence Gastroenterology 2015, 148: s-1036. DOI: 10.1016/s0016-5085(15)33541-1.
  • Radiology in TransplantKim A, Schilsky M. Radiology in Transplant Current Transplantation Reports 2014, 1: 238-245. DOI: 10.1007/s40472-014-0034-5.
  • In Memoriam: H. Ascher Sellner, M.D.Kaler S, Schilsky M. In Memoriam: H. Ascher Sellner, M.D. Annals Of The New York Academy Of Sciences 2014, 1314: iv-iv. DOI: 10.1111/nyas.12449.
  • P319 HYPOTHERMIA IN ACUTE LIVER FAILURE: A MULTI-CENTRE RETROSPECTIVE COHORT ANALYSIS (IT'S ALRIGHT TO BE COOL)Karvellas C, Stravitz R, Battenhouse H, Durkalski V, Lee W, Schilsky M. P319 HYPOTHERMIA IN ACUTE LIVER FAILURE: A MULTI-CENTRE RETROSPECTIVE COHORT ANALYSIS (IT'S ALRIGHT TO BE COOL) Journal Of Hepatology 2014, 60: s173. DOI: 10.1016/s0168-8278(14)60481-5.
  • A multicenter retrospective cohort analysis of therapeutic hypothermia in acute liver failureKarvellas C, Stravitz R, Battenhouse H, Durkalski V, Lee W, Schilsky M. A multicenter retrospective cohort analysis of therapeutic hypothermia in acute liver failure Critical Care 2014, 18: p200. PMCID: PMC4068622, DOI: 10.1186/cc13390.
  • 730McGinniss J, Marshall P, Schilsky M, Honiden S. 730 Critical Care Medicine 2013, 41: a180-a181. DOI: 10.1097/01.ccm.0000439968.28678.d4.
  • Acute Liver and Multi-organ Failure Secondary to Intentional Iron OverdoseRuss K, Khan A, James L, Schilsky M, Fix O, Lee W, McGuire B. Acute Liver and Multi-organ Failure Secondary to Intentional Iron Overdose The American Journal Of Gastroenterology 2013, 108: s324. DOI: 10.14309/00000434-201310001-01086.
  • Wilson DiseaseSchilsky M, Tavill A. Wilson Disease 2011, 803-824. DOI: 10.1002/9781119950509.ch29.
  • Wilson’s DiseaseSchilsky M, Mitchell K. Wilson’s Disease 2010, 5: 655-663. DOI: 10.1007/978-1-4419-7107-4_43.
  • Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ diseaseSchilsky M, Mistry P. Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ disease 2010, 1688-1693. DOI: 10.1093/med/9780199204854.003.120702.
  • Copper Metabolism and the LiverSchilsky M, Thiele D. Copper Metabolism and the Liver 2009, 221-233. DOI: 10.1002/9780470747919.ch15.
  • T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver DiseaseWong R, Gish R, Schilsky M, Frenette C. T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver Disease Gastroenterology 2009, 136: a-844. DOI: 10.1016/s0016-5085(09)63889-0.
  • M1731 Wilson Disease and Outcomes After Liver TransplantationArnon R, Annunziato R, Schilsky M, Miloh T, Suchy F, Iyer K, Kerkar N. M1731 Wilson Disease and Outcomes After Liver Transplantation Gastroenterology 2009, 136: a-420. DOI: 10.1016/s0016-5085(09)61931-4.
  • Reply:Schilsky M, Lee W, Wiands F. Reply: Hepatology 2009, 49: 1784-1784. DOI: 10.1002/hep.22954.
  • Chapter 42 Wilson Disease and the KidneySchilsky M, Mistry P. Chapter 42 Wilson Disease and the Kidney 2009, 709-713. DOI: 10.1016/b978-0-12-449851-8.00042-5.
  • Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's DiseaseBrewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease 2008, 153-166. DOI: 10.1017/cbo9780511666971.010.
  • Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's DiseaseBrewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease Progress In Neurotherapeutics And Neuropsychopharmacology 2007, 3 DOI: 10.1017/s1748232107000043.
  • Chapter 38 The Transplant Operation: What the Hepatologist Should KnowSchilsky M, Kinkhabwala M, Emond J. Chapter 38 The Transplant Operation: What the Hepatologist Should Know 2006, 605-620. DOI: 10.1016/b978-0-323-03675-7.50042-1.
  • Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant RegistryKOWDLEY K, BRANDHAGEN D, GISH R, BASS N, WEINSTEIN J, SCHILSKY M, FONTANA R, MCCASHLAND T, COTLER S, BACON B. Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry Gastroenterology 2005, 129: 494-503. DOI: 10.1016/j.gastro.2005.05.004.
  • Wilson's DiseaseSchilsky M. Wilson's Disease 2004, 643-647. DOI: 10.1016/b0-12-386860-2/00731-0.
  • Corrections: A practice guideline on Wilson diseaseRoberts E, Schilsky M. Corrections: A practice guideline on Wilson disease Hepatology 2003, 38: 536-536. DOI: 10.1002/hep.510380241.
  • Elevation of serum ferritin and survival of patients with acute liver failureKorman J, Schiodt F, Balko J, Lee W, Schilsky M, Group A. Elevation of serum ferritin and survival of patients with acute liver failure Gastroenterology 2003, 124: a756. DOI: 10.1016/s0016-5085(03)83818-0.
  • Mechanism of sestamibi retention and clearance from myocardium and other organsJoseph B, Bhargava K, Kandimalla J, Malhi H, Schilsky M, Palestro C, Jain D, Gupta S. Mechanism of sestamibi retention and clearance from myocardium and other organs Journal Of The American College Of Cardiology 2003, 41: 444. DOI: 10.1016/s0735-1097(03)81349-9.
  • 640 HCV alternate reading frame proteins (ARFPS) may be virulence factors that help the virus survive adverse conditionsBranch A, Walewski J, Gutierrez J, Fernandez E, Im G, Dieterich D, Schiano T, Sigal S, Schilsky M, Schwartz M, Kyrk C, Muerhoff A, Leary T, Stewart J, Dawson G, Desai S. 640 HCV alternate reading frame proteins (ARFPS) may be virulence factors that help the virus survive adverse conditions Hepatology 2003, 38: 468-469. DOI: 10.1016/s0270-9139(03)80682-1.
  • 815 Molecular epidemiology of hepatitis B virus-related acute liver failure in the United States: a multicenter case control studyWai C, Fontana R, Schilsky M, McCashland T, Han S, Polson J, Hussain M, Lee W, Lok A. 815 Molecular epidemiology of hepatitis B virus-related acute liver failure in the United States: a multicenter case control study Hepatology 2003, 38: 555. DOI: 10.1016/s0270-9139(03)80857-1.
  • Inherited metabolic diseaseSchilsky M. Inherited metabolic disease Current Opinion In Gastroenterology 1998, 14: 200-207. DOI: 10.1097/00001574-199805000-00004.
  • Wilson’s DiseaseSchilsky M, Sternlieb I. Wilson’s Disease 1998, 285-292. DOI: 10.1007/978-1-4612-1808-1_21.
  • Genetic HemochromatosisSchilsky M, Sternlieb I. Genetic Hemochromatosis 1998, 241-247. DOI: 10.1007/978-1-4612-1808-1_18.
  • Inherited metabolic diseaseSchilsky M. Inherited metabolic disease Current Opinion In Gastroenterology 1997, 13: 194-198. DOI: 10.1097/00001574-199705000-00004.
  • An array of mitochondrial alterations in the hepatocytes of Long-Evans Cinnamon ratsSternlieb I, Quintana N, Volenberg I, Schilsky M. An array of mitochondrial alterations in the hepatocytes of Long-Evans Cinnamon rats Hepatology 1995, 22: 1782-1787. DOI: 10.1016/0270-9139(95)90206-6.
  • In Vitro modeling of liver membrane copper transports Dijkstra M, Veld GI, van den Berg GJ, Muller M, Kuipers F, Vonk RJ. J. Clin Invest 1995; 95: 412–416Schilsky M. In Vitro modeling of liver membrane copper transports Dijkstra M, Veld GI, van den Berg GJ, Muller M, Kuipers F, Vonk RJ. J. Clin Invest 1995; 95: 412–416 Hepatology 1995, 22: 1340-1342. DOI: 10.1016/0270-9139(95)90651-7.
  • Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transferFox I, Chowdhury N, Gupta S, Kondapalli R, Schilsky M, Stockert R, Chowdhury J. Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transfer Hepatology 1995, 21: 837-846. DOI: 10.1016/0270-9139(95)90539-1.
  • Biochemistry and molecular biology of the liverSchilsky M, Shafritz D. Biochemistry and molecular biology of the liver Current Opinion In Gastroenterology 1992, 8: 418-425. DOI: 10.1097/00001574-199206000-00009.

Clinical Trials

ConditionsStudy Title
Diseases of the Endocrine System; Genetics - AdultA Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)
Genetics - AdultEfficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects
Diseases of the Digestive System - Liver; Diseases of the Eye; Diseases of the Nervous SystemWilson Disease Registry
Hepatitis; HIV/AIDS; Immune System; Infectious DiseasesScreening In Anticipation of Future Research